Bone cancer pain

Cancer

Volumn 97, Issue 3 SUPPL., 2003, Pages 866-873

  Clohisy, Denis R ^a   Mantyh, Patrick W ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bone cancer; Experimental model; Neurochemical markers; Osteolytic sarcoma; Pain

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE CANCER; BONE DESTRUCTION; BONE RADIOGRAPHY; CANCER PAIN; CENTRAL NERVOUS SYSTEM; CONFERENCE PAPER; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MORPHOMETRICS; MOUSE; NEUROPATHIC PAIN; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SARCOMA; SENSITIZATION;

EID: 0037302154     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11144     Document Type: Conference Paper

References (64)

1. Coyle NAJ, Foley KM, Portenoy RK. Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Sympt Manage. 1990;5:83-93.
2. Foley KM. Advances in cancer pain. Arch Neurol. 1999;56: 413-417.
3. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353:1695-700.
4. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129-134.
5. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80:1588-1594.
6. Tong D, Gillick L, Hendrickson FR. The palliation of symptomatic osseous metastases: final results of the study by the Radiation Therapy Oncology Group. Cancer. 1982;50:893-899.
7. Coleman CN, Kaplan ID. Prostate cancer. Technology versus biology [editorial]. Cancer. 1993;72:305-309.
8. Coleman RE. How can we improve the treatment of bone metastases further? Curr Opin Oncol. 1998;10(Suppl 1):S7-S13.
9. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases [see comments]. Clin Chem. 1999;45:1240-1247.
10. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group [see comments]. N Engl J Med. 1996;335:1785-1791.
11. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer. 2000;88:1082-1090.
12. Pelger RC, Hamdy NA, Zwinderman AH, Lycklama a Nijeholt AA, Papapoulos SE. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. Bone. 1998;22:403-408.
13. Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate, Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16:2038-2044.
14. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol. 1999;17:846-854.
15. Clohisy D. Management of skeletal metastasis. In: Edward V, Craig M, editors. Clinical orthopaedics. Philadelphia: Lippincott Williams & Wilkins, 1999:994-997.
16. Clohisy DR, Le CT, Cheng EY, Dykes DC, Thompson RC Jr. Evaluation of the feasibility of and results of measuring health-status changes in patients undergoing surgical treatment for skeletal metastases. J Orthop Res. 2000;18:1-9.
17. Mantyh PW, Koltzenburg M, Hunt SP. Molecular mechanism of cancer pain. Nat Rev Cancer. 2002;2:201-209.
18. Baines M. Pain relief in active patients with cancer: analgesic drugs are the foundation of management. BMJ. 1989;298: 36-38.
19. Clohisy DR, Ogilvie CM, Ramnaraine ML. Tumor osteolysis in osteopetrotic mice. J Orthop Res. 1995;13:892-897.
20. Schwei MJ, Honore P, Rogers SD, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci. 1999;19:10886-10897.
21. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med. 2000;6:521-528.
22. Honore P, Rogers SD, Schwei MJ, et al. Murine models of inflammatory, neuropathic, and cancer pain each generates a unique set of neurochemical changes in the spinal cord and sensory neurons. Neuroscience. 2000;98:585-598.
23. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res. 2001; 61:4038-4047.
24. Mantyh PW, DeMaster E, Malhotra A, et al. Receptor endocytosis and dendrite reshaping in spinal neurons after somatosensory stimulation. Science. 1995;268:1629-1632.
25. Allen BJ, Rogers SD, Ghilardi JR, et al. Noxious cutaneous thermal stimuli induce a graded release of endogenous substance P in the spinal cord: imaging peptide action in vivo. J Neurosci. 1997;17:5921-5927.
26. Fields HL. Can opiates relieve neuropathic pain? Pain. 1988;35:365-367.
27. Fields HL. Pain modulation. Amsterdam: Elsevier, 1988.
28. Attal N, Brasseur L, Parker F, Chauvin M, Bouhassira D. Effects of gabapentin on the different components of peripheral and central neuropathic pain syndromes: a pilot study. Eur Neurol. 1998;40:191-200.
29. Field MJ, McCleary S, Hughes J, Singh L. Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. Pain. 1999;80:391-398.
30. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L. Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol. 1997;121:1513-1522.
31. Marsh D, Dickenson A, Hatch D, Fitzgerald M. Epidural opioid analgesia in infant rats II: responses to carrageenan and capsaicin. Pain. 1999;82:33-38.
32. Ossipov MH, Lopez Y, Nichols ML, Bian D, Porreca F. The loss of antinociceptive efficacy of spinal morphine in rats with nerve ligation injury is prevented by reducing spinal afferent drive. Neurosci Lett. 1995;199:87-90.
33. Pan HL, Eisenach JC, Chen SR. Gabapentin suppresses ectopic nerve discharges and reverses allodynia in neuropathic rats. J Pharmacol Exp Ther. 1999;288:1026-1030.
34. Stanfa L, Dickenson A. Spinal opioid systems in inflammation. Inflamm Res. 1995;44:231-241.
35. Stanfa LC, Singh L, Williams RG, Dickenson AH. Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Neuroreport. 1997;8: 587-590.
36. Safieh-Garabedian B, Poole S, Allchorne A, Winter J, Woolf CJ. Contribution of interleukin-1 beta to the inflammation-induced increase in nerve growth factor levels and inflammatory hyperalgesia. Br J Pharmacol. 1995;115:1265-1275.
37. Donnerer J, Schuligoi R, Stein C. Increased content and transport of substance P and calcitonin gene-related peptide in sensory nerves innervating inflamed tissue: evidence for a regulatory function of nerve growth factor in vivo. Neuroscience. 1992;49:693-698.
38. Donnerer J, Schuligoi R, Stein C, Amann R. Upregulation, release and axonal transport of substance P and calcitonin gene-related peptide in adjuvant inflammation and regulatory function of nerve growth factor. Regul Peptides. 1993; 46:150-154.
39. Cho HJ, Kim JK, Zhou XF, Rush RA. Increased brain-derived neurotrophic factor immunoreactivity in rat dorsal root ganglia and spinal cord following peripheral inflammation. Brain Res. 1997;764:269-272.
40. Cho HJ, Park EH, Bae MA, Kim JK. Expression of mRNAs for preprotachykinin and nerve growth factor receptors in the dorsal root-ganglion following peripheral inflammation. Brain Res. 1996;716:197-201.
41. Villar MJ, Wiesenfeld-Hallin Z, Xu XJ, Theodorsson E, Emson PC, Hokfelt T. Further studies on galanin-, substance P-, and CGRP-like immunoreactivities in primary sensory neurons and spinal cord: effects of dorsal rhizotomies and sciatic nerve lesions. Exp Neurol. 1991;112:29-39.
42. Garrison CJ, Dougherty PM, Carlton SM. Quantitative analysis of substance P and calcitonin gene-related peptide immunohistochemical staining in the dorsal horn of neuropathic MK-801-treated rats. Brain Res. 1993;607:205-214.
43. Noguchi K, Senba E, Morita Y, Sato M, Tohyama M. Prepro-VIP and preprotachykinin mRNAs in the rat dorsal root ganglion cells following peripheral axotomy. Brain Res Mol Brain Res. 1989;6:327-330.
44. Coleman RE, Purohit OP, Vinholes JJ, Zekri J. High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer. 1997;80:1686-1690.
45. Clohisy DR, Ogilvie CM, Carpenter JJ, Ramnaraine ML. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts. J Orthop Res. 1996;14:2-6.
46. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98:1544-1549.
47. Yin JJ, Selander K, Chirgwin JM, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103:197-206.
48. Yoneda T, Sasaki A, Dunstan C, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997;99:2509-2517.
49. Clohisy DR, Ramnaraine ML. Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res. 1998; 16:660-666.
50. Clohisy DR RM, Scully S, Qi M, Van G, Tan HL, Lacey DL. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orchopaed Res. 2000;18:967-976.
51. Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides. 1988;9:165-171.
52. Mach DB, Rogers SD, Sabino MAC, et al. Origins of skeletal pain: sensory and sympathetic intervention of the mouse femur. Neuroscience. 2002;113:156-166.
53. Hill EL, Turner R, Elde R. Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience. 1991;44:747-755.
54. Hill EL, Elde R. Distribution of CGRP-, VIP-, D beta H-, SP-, and NPY-immunoreactive nerves in the periosteum of the rat. Cell Tissue Res. 1991;264:469-480.
55. Tabarowski Z, Gibson-Berry K, Felten SY. Noradrenergic and peptidergic innervation of the mouse femur bone marrow. Acta Histochem. 1996;98:453-457.
56. Hukkanen M, Konttinen YT, Rees RG, Santavirta S, Terenghi G, Polak JM. Distribution of nerve endings and sensory neuropeptides in rat synovium, meniscus and bone. Int J Tissue React. 1992;14:1-10.
57. Dray A. Inflammatory mediators of pain. Br J Anaesthesiol. 1995;75:125-131.
58. Abbadie C, Trafton J, Liu H, Mantyh PW, Basbaum AI. Inflammation increases the distribution of dorsal horn neurons that internalize the neurokinin-1 receptor in response to noxious and non-noxious stimulation. J Neurosci. 1997;17:8049-8060.
59. Allen BJ, Li J, Menning PM, et al. Primary afferent fibers that contribute to increased substance P receptor internalization in the spinal cord after injury. J Neurophysiol. 1999;81:1379-1390.
60. Treede RD, Meyer RA, Raja SN, Campbell JN. Peripheral and central mechanisms of cutaneous hyperalgesia. Progr Neurobiol. 1992;38:397-421.
61. Mantyh PW, Rogers SD, Honore P, et al. Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor [see comments]. Science. 1997;278:275-279.
62. Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity. Nature. 1983;306:686-688.
63. Woolf CJ, Safieh-Garabedian B, Ma QP, Crilly P, Winter J. Nerve growth factor contributes to the generation of inflammatory sensory hypersensitivity. Neuroscience. 1994;62: 327-331.
64. Dickenson AH. A cure for wind up: NMDA receptor antagonists as potential analgesics. Trends Pharmacol Sci. 1990; 11:307-309.